A Phase 3 interventional study of dabigatran etexilate and standard of care in Venous Thromboembolism, sponsored by Boehringer Ingelheim. Completed at 65 sites in 26 countries. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2020-07-07.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing dabigatran in Venous Thromboembolism — 1 open to participants now, 1 under way, none of them phase 3. Dabigatran · Venous Thromboembolism.
Among the 17 studies testing dabigatran in Venous Thromboembolism, this one is the 7th largest by enrollment, is one of 3 that started in 2013, is one of 6 in phase 3, and was the 10th registered.
713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.
Browse Venous Thromboembolism studies →1 of the 17 studies testing dabigatran in Venous Thromboembolism is open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Dabigatran: first FDA approval 2010 (PRADAXA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: Up to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 241 across 402 interventional studies indexed under Venous Thromboembolism.
Median enrollment 148 across the 17 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 6 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
17 studies in Venous Thromboembolism by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 15 finished, 13 (87%) have results posted.
Among the 17 studies in Venous Thromboembolism by Boehringer Ingelheim, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2013, is one of 4 in phase 3, and was the 10th registered.
Boehringer Ingelheim’s Venous Thromboembolism studies by the year they started, since 2000.
1 of the studies testing dabigatran in Venous Thromboembolism that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05735639Imperial College LondonTHRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing dabigatran in Venous Thromboembolism, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 17 in Venous Thromboembolism:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objectives of this large phase IIb/III paediatric study are to assess the efficacy and safety of dabigatran etexilate relative to standard of care and to document the appropriateness of the proposed dabigatran etexilate dosing algorithm for use in patients from birth to less than 18 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Active liver disease, including known active hepatitis A, B or C or, Persistent (ALT) or aspartate transaminase (AST) or alkaline phosphatase (AP) > 3 × (ULN) within 3 months of screening
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dabigatran etexilate capsules, pellets or liquid formulation given BID in an open label fashion for 3 months
Drug: dabigatran etexilate
Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
Drug: standard of care
Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
Low molecular weight heparin, vitamin K antagonist or fondaparinux prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
Composite Primary Endpoint
The primary endpoint was the combined endpoint of the proportions of patients with: * Complete thrombus resolution * Freedom from recurrent VTE * Freedom from mortality related to VTE. The events outlined in the above combined primary endpoint were assessed by radiologists or other such qualified clinicians using an appropriate method such as ultrasound, echocardiography, venography, or CT scan, based on the location of the thrombus and the test used to perform the baseline assessment. The primary efficacy endpoint contained 3 components. Each component was evaluated separately, and only if the criteria for all 3 components were satisfied, the primary endpoint was considered achieved.
Time frame: From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
Freedom From Major Bleeding Events (MBEs)
Freedom from major bleeding events (MBEs), defined as either fatal bleeding, clinically overt bleeding associated with a decrease in haemoglobin of at least 20 g/L in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial or otherwise involves the central nervous system, or bleeding that requires intervention in an operating suite.
Time frame: From first administration of trial medication until last administration of trial medication +6 days (residual effect period). Up to 97 days.
Steady State Plasma Concentrations of Total Dabigatran at Visit 3
Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate at visit 3
Time frame: From the time of randomisation until visit 3
Steady State Plasma Concentrations After at Least 3 Days Following Any Dabigatran Etexilate Dose Adjustment
Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate after at least 3 days following any dabigatran etexilate dose adjustment
Time frame: From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
Frequency of Dose Adjustment During the Treatment Phase
Frequency of dose adjustments (i.e. number of patients with dose adjustment), temporary and permanent discontinuation from therapy, and number of patients with laboratory monitoring requirements for dose
Time frame: From first administration of trial medication until last administration of trial medication +6 days (residual effect period).
Frequency of Patients Switching the Type of Anti-coagulation Therapy Including Dabigatran Etexilate to Standard of Care Treatment and Switching From One Standard of Care Treatment to Another
Frequency of patients switching the type of anti-coagulation therapy including Dabigatran etexilate (DE) to standard of care (SoC) treatment and switching from one standard of care treatment to another. For DE arm, only the switch from DE to SoC was counted, while for the SoC arm, all switches among SoC treatments were counted.
Time frame: From first administration of trial medication until last administration of trial medication +6 days (residual effect period).
Freedom From Thrombus Progression at End of Therapy Compared With Baseline
Freedom from thrombus progression at end of therapy compared with baseline, based on adjudication-confirmed data.
Time frame: From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
All Bleeding Events
The number of participants with bleeding events includes major bleeding events (MBEs), clinically relevant non-major (CRNM) bleeding, minor bleeding events, any bleeding events, and the numbers of the combined endpoint of major and CRNM bleeding events was presented, based on adjudication-confirmed data.
Time frame: From first administration of trial medication until last adminstration of trial medication +6 days (residual effect period). Up to 97 days.
All-cause Mortality
Patients being alive at the end of observational period will be censored for all-cause mortality at the date of patients' last date known to be alive, or the date of data cut-off whichever comes first.
Time frame: From first administration of trial medication until last administration of trial medication +6 days (residual effect period). Up to 97 days.
All Components of the Primary Efficacy Endpoint
Patients with VTE-related death occurring between randomisation to Day 84 + 7 days were considered as not meeting the endpoint. The presence of recurrent VTE(s) was examined throughout the trial, and only the date of first occurrence was used for analysis. Assessment of index VTE status (best overall response) was scheduled on Day 84 ± 7 days (Visit 8) for patients who were alive without an early consent withdraw. In the case a Patient discontinued trial medication prematurely due to any reason the index VTE assessment took place at the early end of treatment visit.
Time frame: From the time of randomisation until Week 12, 84 days after randomisation including a visit window of 7 days.
Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Capsules)
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire capsules: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire capsules: How acceptable was the DE treatment for the child? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Patients questionnaire capsules: Was taking the study capsules easy or difficult? The score is 1 (Very easy), 2 (easy), 3 (neither easy nor difficult), 4 (difficult) and 5 (very difficult). Scores refers to the end of treatment.
Time frame: Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.
Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Pellets)
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire pellets: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire pellets: Do you think that spitting occurs? The score is 1 (Never), 2 (sometimes) and 3 (often). Scores refers to the end of treatment.
Time frame: Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.
Assessment of the Acceptability of an Age-appropriate Formulation at End of Therapy (Oral Liquid Formulation - OLF)
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire flavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Investigator questionnaire unflavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire flavoured OLF.: Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Parents questionnaire unflavoured OLF:Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Scores refers to the end of treatment.
Time frame: Assessment at the last study visit at day 84 (+- 7 days), or at day of early termination.
A multi-centre, open-label, randomised, parallel-group, active-controlled, non-inferiority trial of dabigatran etexilate (DE) versus standard of care (SoC) in children from birth to less than 18 years of age.
| Milestone | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| Started | 177 | 90 |
| Treated | 176 | 90 |
| Completed | 168 | 85 |
| Not completed | 9 | 5 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Not treated | 1 | 0 |
| Withdrew: Other reasons | 3 | 2 |
| Withdrew: Non-compliance with the ctp | 2 | 1 |
The primary endpoint was the combined endpoint of the proportions of patients with: * Complete thrombus resolution * Freedom from recurrent VTE * Freedom from mortality related to VTE. The events outlined in the above combined primary endpoint were assessed by radiologists or other such qualified clinicians using an appropriate method such as ultrasound, echocardiography, venography, or CT scan, based on the location of the thrombus and the test used to perform the baseline assessment. The primary efficacy endpoint contained 3 components. Each component was evaluated separately, and only if the criteria for all 3 components were satisfied, the primary endpoint was considered achieved.
| Participants | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| Complete thrombus resolution | 81 | 38 |
| Freedom from recurrent VTE | 170 | 83 |
| Freedom from mortality related to VTE | 177 | 89 |
| Composite endpoint met | 81 | 38 |
Freedom from major bleeding events (MBEs), defined as either fatal bleeding, clinically overt bleeding associated with a decrease in haemoglobin of at least 20 g/L in a 24-hour period, bleeding that is retroperitoneal, pulmonary, intracranial or otherwise involves the central nervous system, or bleeding that requires intervention in an operating suite.
| Proportion of participants | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| Freedom From Major Bleeding Events (MBEs) | 0.977 (0.948 to 0.990) | 0.977 (0.929 to 0.993) |
Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate at visit 3
| nanogram per milliliter | Dabigatran Etexilate |
|---|---|
| Steady State Plasma Concentrations of Total Dabigatran at Visit 3 | 79.8 ± 68.6 |
Descriptive statistics for steady state plasma concentrations of total dabigatran etexilate after at least 3 days following any dabigatran etexilate dose adjustment
| nanogram per milliliter | Dabigatran Etexilate |
|---|---|
| Steady State Plasma Concentrations After at Least 3 Days Following Any Dabigatran Etexilate Dose Adjustment | 81.7 ± 54.7 |
Frequency of dose adjustments (i.e. number of patients with dose adjustment), temporary and permanent discontinuation from therapy, and number of patients with laboratory monitoring requirements for dose
| Participants | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| With dose adjustment | 63 | 56 |
| With temporary interruption | 25 | 6 |
| Laboratory monitoring required | 175 | 82 |
Frequency of patients switching the type of anti-coagulation therapy including Dabigatran etexilate (DE) to standard of care (SoC) treatment and switching from one standard of care treatment to another. For DE arm, only the switch from DE to SoC was counted, while for the SoC arm, all switches among SoC treatments were counted.
| Participants | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| Frequency of Patients Switching the Type of Anti-coagulation Therapy Including Dabigatran Etexilate to Standard of Care Treatment and Switching From One Standard of Care Treatment to Another | 22 | 2 |
Freedom from thrombus progression at end of therapy compared with baseline, based on adjudication-confirmed data.
| Participants | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| Freedom From Thrombus Progression at End of Therapy Compared With Baseline | 148 | 73 |
The number of participants with bleeding events includes major bleeding events (MBEs), clinically relevant non-major (CRNM) bleeding, minor bleeding events, any bleeding events, and the numbers of the combined endpoint of major and CRNM bleeding events was presented, based on adjudication-confirmed data.
| Participants | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| Any bleeding | 38 | 22 |
| Major bleeding | 4 | 2 |
| CRNM bleeding | 2 | 1 |
| Minor bleeding | 33 | 21 |
| Major and CRNM bleeding | 6 | 3 |
Patients being alive at the end of observational period will be censored for all-cause mortality at the date of patients' last date known to be alive, or the date of data cut-off whichever comes first.
| Participants | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| All-cause Mortality | 0 | 1 |
Patients with VTE-related death occurring between randomisation to Day 84 + 7 days were considered as not meeting the endpoint. The presence of recurrent VTE(s) was examined throughout the trial, and only the date of first occurrence was used for analysis. Assessment of index VTE status (best overall response) was scheduled on Day 84 ± 7 days (Visit 8) for patients who were alive without an early consent withdraw. In the case a Patient discontinued trial medication prematurely due to any reason the index VTE assessment took place at the early end of treatment visit.
| Participants | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| Complete thrombus resolution by Day 84 | 81 | 38 |
| Recurrent VTE by Day 84 | 7 | 7 |
| VTE-related death by Day 84 | 0 | 1 |
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire capsules: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire capsules: How acceptable was the DE treatment for the child? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Patients questionnaire capsules: Was taking the study capsules easy or difficult? The score is 1 (Very easy), 2 (easy), 3 (neither easy nor difficult), 4 (difficult) and 5 (very difficult). Scores refers to the end of treatment.
| Score | Dabigatran Etexilate |
|---|---|
| Investigator questionnaire capsules | 1.0 ± 0.2 |
| Parents questionnaire capsules | 1.0 ± 0.0 |
| Patient questionnaire capsules | 1.6 ± 0.9 |
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire pellets: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire pellets: Do you think that spitting occurs? The score is 1 (Never), 2 (sometimes) and 3 (often). Scores refers to the end of treatment.
| Score | Dabigatran Etexilate |
|---|---|
| Investigator questionnaire pellets | 1.2 ± 0.6 |
| Parents questionnaire pellets | 1.2 ± 0.5 |
Acceptability was defined as the overall ability and willingness of the patient to use the medicinal product. Questions regarding acceptability were to be answered by the patient and/or parent/caregiver (as applicable) and by the investigator/site staff. Investigator questionnaire flavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Investigator questionnaire unflavoured OLF: What is your impression about the patient's acceptability of DE intake? The score is 1 (good), 2 (satisfactory), 3 (not satisfactory) and 4 (bad). Parents questionnaire flavoured OLF.: Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Parents questionnaire unflavoured OLF:Do you think spitting occurs? The score ranges form 1 (never), 2 ( sometimes) to 3 (often). Scores refers to the end of treatment.
| Score | Dabigatran Etexilate |
|---|---|
| Investigator questionnaire flavoured OLF | 1.6 ± 0.8 |
| Investigator questionnaire unflavoured OLF | 1.2 ± 0.4 |
| Parents questionnaire flavoured OLF | 1.4 ± 0.5 |
| Parents questionnaire unflavoured OLF | 1.8 ± 0.4 |
Collected over For DE patients all AEs recorded between first dabigatran etexilate (DE) intake until 6 days after the last administration of dabigatran etexilate. For patients in standard of care arm, all AEs occurred between the first drug intake of standard of care (SOC) until 6 days after the last administration of any standard of care. The Open-label treatment period with DE or SOC is from vist 2 defined as day 0 up to 84 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dabigatran Etexilate | 2/176 (1.1%) | 25/176 (14.2%) | 59/176 (33.5%) |
| Standard of Care | 2/90 (2.2%) | 18/90 (20%) | 16/90 (17.8%) |
| Event | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| Deep vein thrombosisVascular disorders | 2/176 | 3/90 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/176 | 2/90 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/176 | 0/90 |
| HaematocheziaGastrointestinal disorders | 2/176 | 1/90 |
| Sickle cell anaemia with crisisBlood and lymphatic system disorders | 0/176 | 1/90 |
| Cardiac arrestCardiac disorders | 0/176 | 1/90 |
| Cardiac failureCardiac disorders | 0/176 | 1/90 |
| TachycardiaCardiac disorders | 0/176 | 1/90 |
| PapilloedemaEye disorders | 0/176 | 1/90 |
| Peritoneal haemorrhageGastrointestinal disorders | 0/176 | 1/90 |
| Event | Dabigatran Etexilate | Standard of Care |
|---|---|---|
| HeadacheNervous system disorders | 17/176 | 4/90 |
| VomitingGastrointestinal disorders | 14/176 | 1/90 |
| NasopharyngitisInfections and infestations | 11/176 | 7/90 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 8/176 | 6/90 |
| PyrexiaGeneral disorders | 11/176 | 3/90 |
| DyspepsiaGastrointestinal disorders | 10/176 | 0/90 |
| DiarrhoeaGastrointestinal disorders | 9/176 | 1/90 |
The randomised set (RS) included all randomised patients in the treatment groups to which they were randomised, regardless whether they took trial medication
| Age, Continuous(Years) | Dabigatran Etexilate | Standard of Care | Total |
|---|---|---|---|
| Mean | 11.1 ± 6.1 | 11.0 ± 6.1 | 11.1 ± 6.1 |
| Sex: Female, Male(Participants) | Dabigatran Etexilate | Standard of Care | Total |
|---|---|---|---|
| Female | 96 | 38 | 134 |
| Male | 81 | 52 | 133 |
| Ethnicity (NIH/OMB)(Participants) | Dabigatran Etexilate | Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 3 | 11 |
| Not Hispanic or Latino | 169 | 86 | 255 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Dabigatran Etexilate | Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 10 | 3 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 3 | 4 |
| White | 163 | 82 | 245 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2013 to primary completion in Oct 2019, 72 months.
Results were first posted in Jul 2020, 8 months after primary completion.
Of 47 phase 3 interventional studies under Venous Thromboembolism, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 72 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dabigatran